BioStock

Alzinova comments on SEK 50 million rights issue

2025-12-30 08:53:00

From 6 to 20 February, Alzinova will carry out an 80 per cent secured rights issue of units that can initially provide the company with approximately SEK 50 million. The issue is carried out to strengthen the company’s financial position ahead of continued partnership discussions and preparations for phase II with the vaccine candidate ALZ-101. BioStock contacted CEO Tord Labuda and CFO Erik Kullgren to clarify questions regarding the structure and to have a look ahead.

Read more at biostock.se:

Alzinova comments on the issue of SEK 50 million

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden